To help inform the Commission’s work on high-cost specialty drugs, MACPAC contracted with NORC to conduct an analysis of specialty drugs currently in Phase I-III trials or under review by the Food and Drug Administration.
NORC created a framework for prioritizing the pipeline, including a broader focus on high-cost gene and cell therapies, as well as products used to treat conditions with higher prevalence in Medicaid. To inform the analysis of specialty pipeline products that are likely affect the Medicaid program, Acumen conducted a prevalence analysis of conditions that are the targets of these therapies, using Medicaid administrative data.